Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease-Reference-Cited by-同舟云学术

Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease

Published:2020-11-19 Issue:2 Volume:32 Page:201-207
ISSN:0954-691X
Container-title:European Journal of Gastroenterology & Hepatology
language:en
Short-container-title:

Author:

Lovero Rosa,Losurdo Giuseppe,La Fortezza Rosa Federica,Terracciano Fulvia,Biscaglia Giuseppe,Martino Giuseppina,Nardella Marianna,Di Leo Alfredo,Principi Mariabeatrice,Andriulli Angelo,Bossa Fabrizio

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference25 articles.

1. Etiopathogenesis of inflammatory bowel disease: today and tomorrow.;de Souza;Curr Opin Gastroenterol,2017

2. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn’s disease in deep remission under treatment with anti-TNFα antibodies.;Tursi;J Gastrointestin Liver Dis,2014

3. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.;Ierardi;J Clin Pathol,2011

4. Infliximab for induction and maintenance therapy for ulcerative colitis.;Rutgeerts;N Engl J Med,2005

5. ECCO Guidelines on therapeutics in Crohn’s Disease: medical treatment.;Torres;J Crohns Colitis,2020

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease;Expert Opinion on Biological Therapy;2024-07-02

2. Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching;BioDrugs;2024-03-23

3. Clinical Outcomes and Patient Experience of Biosimilar to Biosimilar Infliximab Switching in Patients with Inflammatory Bowel Disease: A Prospective, Single-Centre, Phase IV Interventional Study with a Nested Qualitative Study;GastroHep;2023-08-25

4. Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea;Advances in Therapy;2023-01-10

5. Safety and Effectiveness of Multiple Switching Between Originators and Biosimilars: Literature Review and Status Report on Interchangeability;Therapeutic Innovation & Regulatory Science;2022-11-02